REPLIMUNE GROUP INC shares rose nearly 68% Friday after reaching an agreement to resubmit its skin cancer drug application to the United States regulator. The FDA twice declined to approve the therapy, most recently in April, citing the lack of a well-controlled trial. A successful resubmission would mark the drug's third regulatory attempt and provide a new combination therapy option for the estimated 112,000 Americans diagnosed with melanoma annually.

Overcoming Regulatory Hurdles for RP1